MicroPort Scientific : First Evolution™ Total Knee Replacement Completed in Heilongjia...

Heilongjiang, China - On December 19, a surgery using MicroPort Orthopedics' second-generation total knee replacement system Evolution™ Medial-Pivot Knee System ('Evolution™') was completed in the First Affiliated Hospital of Harbin Medical University of Heilongjiang Province, which marked the first implantation of Evolution™ in Heilongjiang.

The female patient, 59, suffered from osteoarthritis in her right knee. The surgery was performed by Professor Weiliang Yang who finished the prosthesis fitting in 30 minutes. Professor Yang spoke highly of Evolution™'s stable performance and its sizing profile. He also noted, its matching tools are easy to use and provide great help for surgeons during the operation. Professor Yang said he looks forward to seeing Evolution™ benefit more Chinese patients.

Postoperative stability is an important indicator to determine the outcome of a knee replacement surgery as well as the patient's motion and experience after the surgery. Evolution™ features medial pivot design, ball-in-socket articulation, and slideway in lateral side, which enhances stability and allows the prosthesis to move and feel more like a normal knee. Evolution™ aims to provide an implant that delivers low bone cut, wear limiting design, flexion stability, and high patient satisfaction. In addition, it facilitates faster return to function as it protects the muscle strength of quadriceps femoris.

As the second-generation medial pivot knee of MicroPort Orthopedics, Evolution™ imitates the natural motion of the knee by incorporating a patented ball-in-socket feature on the medial side, which enhances stability and allows the prosthesis to move and feel more like a normal knee. Such design is in line with the latest development trend of knee prosthesis. At the same time, Evolution™ provides better flexion to meet the needs of daily life for most Asian patients, making it easier for them to go upstairs, kneel, and sit on heels. In this way, the system answers the traditional implant limitations to better balance stability and mobility.

As one of the well-known knee systems in the world, Evolution™ has gained high market recognition after launched in the US in 2010 and subsequently sold to Europe and Japan. It entered the Chinese mainland market and Hong Kong market in 2015. The completion of the first case in Heilongjiang Province means MicroPort Orthopedics will further expand the China market to provide better orthopedic products and innovative solutions for surgeons and patients.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:

Sophie Wei Senior Corporate Culture Manager Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-8018 Email: [e-mail]